A Revolutionary Approach to Cancer Treatment


Jounce Therapeutics, Inc. (NASDAQ: JNCE) is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefit to patients. Jounce utilizes its Translational Science Platform to first focus on specific cell types within tumors to prioritize targets, and then identify related biomarkers designed to match the right therapy to the right patient.


Year Invested: 2013
Location: Cambridge, Mass.
Visit: www.jouncetx.com

Recent News

August 30, 2017
Jounce Therapeutics to Present at Upcoming Investor Conferences in September

August 15, 2017
Jounce Therapeutics Names Hugh Cole as Chief Business Officer and Head of Corporate Development

August 9, 2017
Jounce Therapeutics Reports Second Quarter 2017 Financial Results

Read More News

Associated Team Members

Robert Tepper, M.D.
Partner

Cary Pfeffer, M.D.
Partner

Perry Karsen
Venture Partner

Robert Kamen, Ph.D.
Entrepreneur-in-Residence